STATE COLLEGE, Pa., May 4 /PRNewswire/ -- SpectruMedix LLC and Capital Genomix have announced today that they have entered into a world-wide, exclusive distribution agreement to market and sell GeneSystem320(TM) (GS320(TM)) for capillary electrophoresis-based applications. Dr. Jill Ray, PhD, Vice President of R&D at Capital Genomix describes the platform as a "method for differential gene expression analysis that exceeds the capabilities of other currently available products." GeneSystem320 (GS320(TM)) is the first simple, unbiased and complete gene expression analysis solution. The GS320 technology is a rapid method to detect and identify all transcripts present at very low levels. Besides its abilities for known gene analysis it is also suited for discovery processes, molecular diagnostics and many other applications in biotechnology.
According to Kevin Gutshall, Director of Sales and Business Development at SpectruMedix LLC, "the powerful and flexible GS320 System coupled with the high throughput SpectruMedix Reveal Genetic Analysis System will allow for rapid and complete genome analysis to detect known transcripts as well as identify novel transcripts." The two companies are completing the validation procedure and will launch the new product early in the third quarter of 2005. The combination of a powerful chemistry and instrumentation platform will enable researchers to rapidly perform assays at a depth and accuracy level that is currently unavailable to the life science researcher. This approach will be a more exhaustive and flexible approach to gene expression than can be achieved using gene chips.
About SpectruMedix, LLC
SpectruMedix LLC is an innovative manufacturer of high throughput capillary electrophoresis instrumentation for genetic analysis. The company's proprietary technology for on-column detection of DNA and temperature gradient capillary electrophoresis allows SpectruMedix to address an unmet need for high throughput screening for mutations present in DNA samples as well as a number of other genetic analysis applications. Systems are available in 24, 96, 192, and 384 capillary configurations.
More information on the Reveal(TM) System can be obtained from http://www.spectrumedix.com/ .
About Capital Genomix, Inc.
Capital Genomix, Inc. is a biotechnology company headquartered in Gaithersburg, Maryland that provides a unique, comprehensive solution for the discovery and rapid development of novel antibody-based therapeutics. These technologies facilitate gene detection and discovery and antibody development. There is an incomplete understanding of the Human Genome and improvements in gene discovery are key to drug development. The company has a strong scientific package to offer perspective clients. Capital Genomix possesses two powerful and proprietary genomic and proteomic drug development technology platforms:
* GeneSystem320(TM) for the discovery and analytical study of genes and
gene expression, and
* ImmunoMouse(TM) for the rapid generation of specific antibodies against
gene sequences of biological and clinical significance.
Capital Genomix intends to utilize these technologies to enable biopharmaceutical collaborators to go from gene study and discovery through function analysis and target validation and directly to potential therapeutic agents and diagnostic targets. More information on the GS320(TM) and other CGI products can be obtained from http://www.capitalgenomix.com/ .
CONTACT: Kevin Gutshall, Director of Sales and Business Development ofSpectruMedix LLC, +1-814-867-8600, ext. 266; or Ron Helminiak, Senior DirectorBusiness Development of Capital Genomix, +1-301-977-3224